Tag:

India

Latest Headlines

Latest Headlines

Wockhardt smacked by state regulator in India

Some Indian regulators appear to have heeded FDA Commissioner Margaret Hamburg's call to set a higher bar for manufacturing quality. India's Wockhardt, already in deep trouble with the U.S. and Europe for slacking off on quality, says one of its products has been banned by a state regulator in Himachal Pradesh.

GSK plans to unload site of closed Indian API plant

GlaxoSmithKline closed an aging active pharmaceutical plant in Thane, Maharashtra, India, a couple of years ago and let go of more than 300 people who worked there. Now, the British drugmaker would like to unload the property.

FDA tags yet another Indian drugmaker, Canton Labs, with ban

The FDA sent a warning letter to Canton Laboratories in Vadodara, India, in February for a list of serious infractions, including falsifying data. The agency has taken the next step, issuing an import alert that bans products from the facility.

Lupin recalls more Suprax on purity problems, adding to Indian pharma's quality questions

In the latest black eye for India's pharma industry, Lupin is recalling some 10,000 bottles of its Suprax antibiotic in the U.S. The pills fell short of standards for purity, the FDA said in a statement on its website.

Cheminformatics skills shortage threatens Indian drug discovery program

The Open Source Drug Discovery program India set up in 2008 promised to disrupt the current model and deliver new treatments for neglected diseases. Six years later, OSDD is still working towards these goals, but has run up against shortages in two age-old areas: Money and skills.

Natco looking to block Indian patent for Gilead's Sovaldi

India may now be taking compulsory licensing one step further, with domestic Natco Pharma asking the country's patent office to deny Gilead Sciences protection on its brand-new hep C treatment in the first place.

Indian authority withdraws Ranbaxy plant export permit

Indian authorities, who have been criticized for turning a blind eye to serious problems at Ranbaxy Laboratories plants there, have stopped a Ranbaxy API plant in Toansa from being able to sell products outside of India.

Novartis fighting two-pronged legal battle in India on Galvus patent

Novartis, already in a legal battle to try to keep India's Wockhardt from launching a generic of its diabetes blockbuster Galvus, says it is now trying to prevent Biocon from doing the same thing.

Canadian drugmaker's Indian plant joins FDA import ban parade

The FDA has banned a handful of plants from some of India's biggest drugmakers in the last year, actions that have led to grumbling that the regulator is picking on Indian-owned operations. But now a plant in India owned by a Canadian firm has gotten the same treatment, an import alert that blocks products from being shipped to the U.S.

Apotex plant in India tagged with import ban

The FDA has again issued an import alert against a plant owned by Canadian generic drugmaker Apotex, this one in India. The last time the agency took that kind of action, Apotex took the matter to international authorities in a North American Free Trade Agreement complaint.